A freight-forwarding group based in a neutral jurisdiction receives a notice: one of its overseas subsidiaries has been added to the Entity List (the Bureau of Industry and Security's register of parties subject to enhanced export-control licence requirements under the Export Administration Regulations). Shipments halt. Banking relationships stiffen. Suppliers in three continents ask uncomfortable questions. The managing partner's first call is to compliance counsel – but the filing that follows is inadequately supported, and the petition stalls. That sequence, in various forms, is one we see repeatedly in cross-border export-control practice.
A delisting petition under the BIS / EAR (the Export Administration Regulations, administered by the Bureau of Industry and Security) is the formal mechanism by which an entity added to the Entity List, the Denied Persons List, or the Unverified List seeks removal or modification of its listing. The process requires a written submission to the End-User Review Committee – a multi-agency body – demonstrating that the concerns underlying the listing have been resolved or were misconceived. As of February 2026, the process is procedurally exacting and the evidentiary standard, while not codified in precise rules, is demanding in practice.
This case comment walks through a representative matter: the situation that triggered the listing, the errors in the first petition, the corrective strategy we applied, the cross-regime complications that emerged, and the lessons that apply to any business facing a comparable position.
The Situation: How the Entity List Placement Arose
Entity List placements under the EAR arise when BIS determines that a party poses an unacceptable risk of diverting controlled goods, software, or technology contrary to US national-security or foreign-policy interests. The placement does not require a criminal conviction, a finding of prior violation, or any advance notice to the listed party. It is an administrative action, not a judicial one.
In the matter we are describing – anonymised throughout – a mid-sized industrial-equipment distributor operating across two continents found that one of its regional trading subsidiaries had been designated on the Entity List. The trigger was a pattern of transaction activity that BIS assessed as indicating a risk of diversion to an end-user of concern. The subsidiary had not received prior notice. It learned of the listing when a US supplier declined to process an export licence application that cited it as the consignee.
The immediate effect was severe. Under the EAR, an Entity List placement subjects the listed party to a licence requirement for the export, re-export, or in-country transfer of items subject to the EAR. The default licensing policy is "presumption of denial" for many categories. In practice, this means that US-origin goods, technology, and software – and many non-US goods containing US-controlled content above the applicable de minimis threshold – became unavailable to the subsidiary without an approved licence that would, in most circumstances, not be granted.
The parent group's operations were materially disrupted within days. Contracts with US and European principals could not be performed. The subsidiary's bank accounts attracted enhanced scrutiny. Trade-finance facilities were suspended pending clarification of the group's compliance status.
The First Petition: Where It Went Wrong
The first petition was filed by in-house counsel without specialist export-control advice. It failed to address the standard that the End-User Review Committee applies and, in two respects, made the position worse.
The petition led with a legal argument: it contended that the administrative record was insufficient to support the listing. That argument, while not without merit in principle, is the wrong instrument for the forum. The End-User Review Committee is not a judicial or quasi-judicial tribunal. It does not conduct adversarial review of its own prior determinations in the way a court would. A petition that reads as a challenge to the regulators' reasoning tends to reinforce concern rather than dissolve it.
The second error was structural. The petition presented corporate documentation – ownership charts, constitutional documents, director registers – without connecting that material to the specific concerns that BIS had raised. The committee's published expectations make clear that a petition must address the substantive basis for the listing. A general assertion of corporate good standing does not do that work.
Third, and most damaging, the petition omitted any concrete description of the compliance measures the group had put in place after the listing. In our experience, the committee treats the period after listing as a window of demonstrated rehabilitation. A petition that says nothing about post-listing conduct signals that the applicant does not understand what it is being asked to show.
The result was a request for additional information that extended the timeline by several months and required the group to produce a substantially revised submission.
What Does the End-User Review Committee Require?
The End-User Review Committee – a multi-agency body that includes representatives from the Departments of Commerce, State, Defense, Energy, and the Treasury – reviews delisting petitions against the same substantive criteria that govern original designations: whether the listed party poses an unacceptable risk of contributing to activities contrary to US national-security or foreign-policy interests.
A well-constructed petition therefore does three things. First, it addresses the factual basis for the listing directly: it either explains why the underlying activity was mis-characterised, or it concedes the activity and demonstrates remediation. Second, it evidences the structural changes that have been made – updated compliance programmes, enhanced due-diligence procedures, revised counterparty approval processes, personnel changes where those are relevant. Third, it provides assurance of future conduct: auditable commitments, if appropriate supported by a third-party compliance assessment, that the conduct giving rise to concern will not recur.
There is no published adjudicative standard equivalent to a "balance of probabilities" or a "clear and convincing evidence" test. The process is executive rather than judicial. That makes contextual judgment by experienced counsel more important, not less. A petition that reads as if it were drafted for a court will often miss the register that moves a committee.
Is there a right of appeal if the petition is refused? The short answer is: not through a straightforward administrative appeal track. A refused petition may be resubmitted, and judicial review in a federal court is theoretically available, but that route is costly, time-consuming, and the applicable standard of review is deferential to the agency. Resubmission with improved evidence is generally the more productive path.
The Corrective Strategy: Rebuilding the Submission
When the group engaged Calder & Vance, the first task was to understand what the listing notice said and what the existing petition had put in front of the committee. We then advised on a structured evidence package designed for the committee's actual decision-making process.
The evidence package had four components. The first was a factual narrative that addressed the transactions that had triggered BIS's concern. This required the group to conduct a detailed internal review of the transaction chain, produce documentary evidence of the stated commercial purpose, and explain the counterparty relationships in enough detail that the committee could assess the risk profile independently. We worked alongside the group's internal compliance team and, where document gaps arose, guided the group on how to address them transparently rather than around them.
The second component was a compliance-programme assessment. The group had, after the listing, engaged an independent compliance consultancy to review and redesign its export-control procedures. We used that report as a structural anchor, presenting its findings and the group's response in a format the committee could interrogate. The redesigned programme covered item classification, licence-determination processes, end-use and end-user screening, and record-keeping to the applicable regulatory standard.
The third component addressed personnel and governance. Where the original transaction activity had involved individuals who were no longer with the group, that was documented. Where it had involved process failures that had since been corrected at a governance level, the board-level actions taken were set out with supporting minutes and policy documents.
The fourth component – and one the original petition lacked entirely – was a forward-looking compliance commitment. This is not a guarantee of outcome, and we do not frame it as one. It is a structured undertaking, backed by documented procedure and governance, that the committee can assess as credible or otherwise. In our cross-border practice we have found that this element, properly constructed, carries more weight than any volume of historical argument about the merits of the original listing.
Cross-Regime Complications: Where BIS Meets Other Controls
An Entity List placement under the EAR does not exist in isolation. For a group with operations and counterparties across multiple jurisdictions, the BIS listing triggered consequences under several other regimes simultaneously.
The most immediate cross-border effect arose from the de minimis rule under the EAR: items subject to EAR controls that contain US-controlled content above the applicable threshold remain subject to US jurisdiction even when re-exported by a non-US party. For a European supplier to the listed subsidiary, this meant that goods it regarded as entirely outside US jurisdiction were in fact subject to re-export licence requirements. Those suppliers faced their own exposure. Several paused supply pending legal review.
The EU position was also relevant. The listed subsidiary's parent group operated within EU territory, and its principals were subject to EU dual-use rules as well as the US EAR. The divergence between the two regimes matters in practice. Under EU dual-use rules, the relevant control trigger is the classification of the item and the stated end-use; a US Entity List placement does not automatically translate into a prohibition under EU law, but it is a material factor in any end-user due-diligence assessment. EU-based suppliers who became aware of the US listing were required to consider whether to exercise their own catch-all controls – the provision allowing controls to be applied to items not otherwise listed where there is knowledge or reason to suspect a prohibited end-use or end-user.
The UK position mirrored this. ECJU guidance on end-user due diligence treats adverse information about a counterparty – including foreign regulatory adverse listings – as a factor that increases the scrutiny a UK exporter must apply before relying on an existing open or standard licence. In one instance, a UK principal suspended deliveries to the group's European distribution hub pending a formal review of whether the hub was itself implicated by the subsidiary's position.
For the group's trade-finance arrangements, the Entity List placement interacted with OFSI and bank compliance obligations. Although an Entity List placement is not a financial-sanctions designation – it does not freeze assets or prohibit financial transactions in the way an OFAC SDN or an OFSI-designated person designation would – banks operating under enhanced compliance programmes treated it as a red flag requiring senior sign-off on any payments involving the listed entity. In practice, the distinction between export-control listing and financial-sanctions designation is not always well understood at the operational level of financial institutions. That gap creates real-world disruption for the listed business, regardless of the technical legal position.
We co-ordinated with local counsel in the relevant jurisdictions to manage the EU and UK aspects of the matter, ensuring that the group's engagement with its European principals was legally coherent with the US delisting strategy rather than running parallel to it without reference.
The position above covers the standard cross-border complications. Your facts – the goods, the routes, the jurisdictions of your principals, the nature of the listing – change the analysis materially.
For a confidential assessment of your exposure across regimes, contact Calder & Vance at info@caldervance.com.
Risk Flags: When a Delisting Petition Becomes More Complex
Not all Entity List placements are equally tractable. Certain features of a listing significantly increase the difficulty of a successful petition, and experienced counsel will identify them at the outset rather than discover them mid-process.
The first risk flag is a connection to a Military End-User or Military Intelligence End-User designation. Under the EAR, these designations reflect a heightened assessment of risk. A petition that must address a military-end-user concern requires more than a standard compliance-programme narrative; it requires a root-and-branch examination of the supply chain and counterparty relationships, and the evidentiary threshold in practice is considerably higher.
The second risk flag is concurrent criminal exposure. Where BIS has made a referral to the Department of Justice, or where there is an open criminal investigation relating to the same underlying conduct, the delisting petition process interacts with criminal procedure in ways that require careful management. Statements made in a civil administrative petition can have implications for a criminal matter. The two tracks must be co-ordinated, and the strategy for each must be designed with the other in view.
The third risk flag is a multi-party listing: where the group entity, its parent, and one or more affiliates have all been added to the list in the same administrative action. This is not uncommon when BIS concludes that a diversion network operates across several legal entities. A petition strategy in that scenario must address each entity's position individually while being consistent across the group. An inconsistency between the petition for entity A and the petition for entity B will be noticed and will undermine both.
The fourth flag is timing. Entity List placements are reviewed periodically, but the timeline for a petition is not fixed by statute. In our experience, the period between submission and a substantive response varies considerably, and the business disruption runs for the duration. The case for early, well-prepared submission – rather than a rapid submission that requires later correction – is strong. A poorly prepared petition that generates a request for additional information effectively resets the clock.
Have you considered whether any concurrent regulatory matter, in any jurisdiction, might affect what your petition says? That question should be asked before the first word is drafted.
A Persistent Myth: "The Listing Must Be Wrong, So the Petition Will Succeed"
The most common misconception we encounter from clients facing a BIS Entity List placement is that if the underlying facts were mischaracterised or misunderstood, the listing will be reversed promptly once that is explained. That belief has a surface logic. But it does not reflect how the process works.
The End-User Review Committee is not an errors-and-omissions tribunal. It does not operate on the basis that a factual correction, however clear, automatically generates a removal. The committee's mandate is forward-looking as well as retrospective: it asks whether the listed party poses a risk going forward, not merely whether it was correctly characterised in the original listing notice. A petition that addresses only the past – however persuasively – without addressing the present and future is likely to be insufficient.
Moreover, the evidentiary asymmetry is real. The listed party does not have access to the full administrative record that led to the listing. Classified or law-enforcement-sensitive information may have informed the decision and will not be disclosed. A petition must therefore be designed to address the plausible range of concerns, not merely the concerns the petitioner can infer from the public-facing listing notice.
There is a related myth in the cross-border context: that because an EU or UK regulator has not taken action against the entity, the BIS position must be overstated. Regimes diverge, however. A US Entity List placement and an EU or UK adverse listing are separate determinations made under separate instruments by separate authorities applying separate legal tests. The absence of action under one regime says nothing definitive about the merits of the position under another. We regularly advise clients who are managing a US listing while simultaneously operating within EU and UK compliance frameworks that treat the entity's status very differently.
If a transaction has already been flagged, or a petition has been refused or stalled, an early specialist review can preserve options that narrow with time. Contact Calder & Vance at info@caldervance.com for a confidential initial assessment.
Lessons for Businesses Facing a BIS Entity List Placement
The principal lesson of this matter – and of similar cases in our practice – is that the quality of the first petition determines much of what follows. A poorly constructed first petition does not merely fail: it creates an adversarial procedural record that a resubmission must overcome as well as address the substantive merits.
The practical lessons are these. First, engage specialist export-control counsel before filing. The petition process is not a form-filling exercise; it requires substantive legal judgment about what the committee is looking for and how to present the evidence in a format that addresses the committee's actual decision-making criteria.
Second, invest in the internal review. The factual narrative at the heart of a successful petition depends on a genuine understanding of the transactions and relationships that triggered the listing. That understanding is produced by a disciplined internal investigation, not by a rapid summary review. Gaps in the factual record are not neutral – they invite inference.
Third, treat the compliance-programme evidence as primary, not secondary. The committee is assessing risk going forward. A well-documented, independently assessed compliance programme is the most direct response to a forward-looking risk assessment. It should be the centrepiece of the petition, not an appendix.
Fourth, address the cross-regime dimension from the outset. If the entity has relationships with EU or UK principals, those principals' regulatory positions need to be understood and managed in a way that is consistent with the US delisting strategy. A fragmented approach – dealing with BIS in isolation while European principals manage their own exposure without reference to the petition strategy – creates the risk of inconsistent statements and inconsistent conduct that the committee and the principals' regulators may both notice.
Fifth, do not wait for the listing to stabilise before reviewing the group's broader supply chain for residual EAR exposure. The de minimis and foreign direct product rules mean that the listed entity's position may create licensing requirements for non-US parties in the supply chain who have not previously assessed their EAR exposure. Addressing that proactively, rather than reactively when a supplier or bank raises the question, reduces the duration and severity of the commercial disruption.
Related practices
- Delisting evidence package – Australia – building the evidence package for removal from Australian autonomous-sanctions designations
- Delisting petition – cross-border matter – managing simultaneous delisting petitions across multiple regimes
- Designation criteria challenge – SECO matter – challenging a Swiss designation on grounds that the listing criteria were not met